Siste forsøk

EudraCT Number: 2022-002407-37

Sponsor Protocol Number: BET-PSMA-121

Start Date: 2023-05-22

Sponsor Name: Blue Earth Therapeutics Limited

Full Title: An open-label, multicentre, integrated Phase 1 & 2 study to evaluate the safety, tolerability, radiation dosimetry and anti-tumour activity of Lutetium (177Lu) rhPSMA-10.1 injection in men with met...

Medical condition: PSMA-positive metastatic castration-resistant prostate cancer (mCRPC)

Disease:	Version	SOC Term	Classification Code	Term	Level
	21.1	100000004864	10076506	Castration-resistant prostate cancer	LLT

Population Age: Adults, Elderly

Gender: Male

Trial protocol: DE (Ongoing)

Trial results: (No results available)

EudraCT Number: 2022-001781-35

Sponsor Protocol Number: UKER-BC007-01

Start Date: 2023-05-16

Sponsor Name: Universitätsklinikum Erlangen

Full Title: Prospective, explorative, randomized, controlled, double-blind, cross-over phase IIa clinical trial to investigate safety and tolerability as well as potential clinical effects of BC007 in patients...

Medical condition: Post-COVID syndrome

Disease:	Version	SOC Term	Classification Code	Term	Level
	24.0	100000004862	10085505	Post-COVID syndrome	LLT

Population Age: Adults, Elderly

Gender: Male, Female

Trial protocol: DE (Ongoing)

Trial results: (No results available)

EudraCT Number: 2022-003865-39

Sponsor Protocol Number: WSG-AM12

Start Date: 2023-05-04

Sponsor Name: Westdeutsche Studiengruppe GmbH

Full Title: NeoAdjuvant Dynamic marker - Adjusted Personalized Therapy comparing trastuzumab-deruxtecan versus pacli-/docetaxel+carboplatin+trastuzumab+pertuzumab in HER2+ early breast cancer

Medical condition: HER2+ early breast cancer

Disease:	Version	SOC Term	Classification Code	Term	Level
	20.0	10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)	10006192	Breast cancer NOS	LLT
	23.0	10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)	10065430	HER2 positive breast cancer	PT

Population Age: Adults, Elderly

Gender: Female

Trial protocol: DE (Ongoing)

Trial results: (No results available)

EudraCT Number: 2023-000033-33

Sponsor Protocol Number: 83631

Start Date: 2023-05-03

Sponsor Name: Maastricht University

Full Title: Short-term safety and efficacy of ketohexokinase inhibition in patients with hereditary fructose intolerance.

Medical condition: Hereditary fructose intolerance

Disease:	Version	SOC Term	Classification Code	Term	Level
	20.0	10010331 - Congenital, familial and genetic disorders	10019878	Hereditary fructose intolerance	PT
	20.1	10010331 - Congenital, familial and genetic disorders	10017397	Fructose intolerance hereditary	LLT
	21.0	10027433 - Metabolism and nutrition disorders	10072104	Fructose intolerance	PT

Population Age: Adults, Elderly

Gender: Male, Female

Trial protocol: NL (Ongoing)

Trial results: (No results available)

EudraCT Number: 2022-003056-14

Sponsor Protocol Number: VTX958-203

Start Date: 2023-05-03

Sponsor Name: Ventyx Biosciences, Inc

Full Title: A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of VTX958 in Patients with Active Psoriatic Arthritis

Medical condition: Active Psoriatic Arthritis

Disease:	Version	SOC Term	Classification Code	Term	Level
	21.0	100000004859	10037160	Psoriatic arthritis	LLT

Population Age: Adults, Elderly

Gender: Male, Female

Trial protocol: DE (Ongoing) CZ (Ongoing) ES (Ongoing) HU (Ongoing) BG (Ongoing)

Trial results: (No results available)

EudraCT Number: 2022-003452-14

Sponsor Protocol Number: SBC007C401

Start Date: 2023-05-02

Sponsor Name: Berlin Cures GmbH

Full Title: A prospective, double-blind, randomised, parallel group, placebo controlled, multicentre, Phase II study to investigate the efficacy, GPCR autoantibody neutralising effect, safety, and tolerability...

Medical condition: long Covid

Disease:	Version	SOC Term	Classification Code	Term	Level
	25.1	100000004862	10087832	COVID-19 rebound	LLT

Population Age: Adults, Elderly

Gender: Male, Female

Trial protocol: DE (Ongoing) FI (Ongoing)

Trial results: (No results available)

EudraCT Number: 2021-005551-36

Sponsor Protocol Number: NL79416.018.21

Start Date: 2023-05-01

Sponsor Name: Amsterdam University Medical Center, AMC

Full Title: Clinical Outcome and Cost-effectiveness of Reduced Noradrenaline by Using a Lower Blood Pressure Target in Patients with Cardiogenic Shock from Acute Myocardial Infarction: A Multicenter Randomized...

Medical condition: Myocardial infarction related cardiogenic shock

Disease:

Version

SOC Term

Classification Code

Term

Level

Population Age: Adults, Elderly

Gender: Male, Female

Trial protocol: DK (Ongoing)

Trial results: (No results available)

EudraCT Number: 2022-003866-19

Sponsor Protocol Number: 83336

Start Date: 2023-05-01

Sponsor Name: Amsterdam UMC location AMC

Full Title: The effect of low-dose rhythmic 17-β-estradiol administration on bone turnover in postmenopausal women

Medical condition: Osteoporosis prevention

Disease:

Version

SOC Term

Classification Code

Term

Level

Population Age: Adults

Gender: Female

Trial protocol: NL (Ongoing)

Trial results: (No results available)

EudraCT Number: 2022-003810-35

Sponsor Protocol Number: BMX-04-001

Start Date: 2023-04-25

Sponsor Name: BiomX Ltd.

Full Title: A Phase 1b/2a, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate Nebulized Bacteriophage Treatment in Outpatient Adult Cystic Fibrosis (CF) Subjects with Chronic Pseudomon...

Medical condition: Cystic fibrosis Chronic Pseudomonas Aeruginosa Infection

Disease:	Version	SOC Term	Classification Code	Term	Level
	20.0	10010331 - Congenital, familial and genetic disorders	10011763	Cystic fibrosis lung	PT
	22.1	100000004862	10082869	Chronic Pseudomonas aeruginosa infection	LLT

Population Age: Adults, Elderly

Gender: Male, Female

Trial protocol: ES (Ongoing) CZ (Ongoing)

Trial results: (No results available)

EudraCT Number: 2022-003408-33

Sponsor Protocol Number: ESR-21-21536

Start Date: 2023-04-25

Sponsor Name: TheraOp gGmbH

Full Title: PACCELIO - FDG-PET based small volume accelerated immuno chemoradio-therapy in locally advanced NSCLC

Medical condition: Locally advanced, unresectable non-small-cell lung cancer (NSCLC) (Stage III) with a PD-L1-expression of ≥ 1%

Disease:	Version	SOC Term	Classification Code	Term	Level
	21.1	10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)	10029519	Non-small cell lung cancer stage III	PT

Population Age: Adults, Elderly

Gender: Male, Female

Trial protocol: DE (Ongoing)

Trial results: (No results available)

Siste forsøk

Sponsorer og samarbeidspartnere

Medisinsk tilstand

Legemiddelintervensjoner